- recruitingPHASE3
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
This study is testing a new drug, capivasertib, for advanced breast cancer that's grown despite previous treatment. It aims to see how well it works and if it improves quality of life for patients.
Belgium · Germany · Portugal - active not recruitingPHASE3
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
This study is looking at whether a medicine called Denosumab can work just as well when given less often (every 12 weeks instead of every 4 weeks) for people with breast or prostate cancer that has spread to their bones. We want to see if we can reduce side effects and costs without losing its benefits.
Austria · Germany · Switzerland - recruitingPHASE3
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
This study compares two treatments for advanced breast cancer. It looks at lasofoxifene with abemaciclib versus fulvestrant with abemaciclib for ER+/HER2- breast cancer that has a specific gene change (ESR1 mutation) and has grown after previous treatment.
United States · Australia · Belgium - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multi-Center, Randomized, Open-Label Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan
This study is testing a new medicine, BDC-1001, for advanced breast cancer that has spread. It's for people whose cancer has a specific marker called HER2. We want to see how well BDC-1001 works alone and with another drug, pertuzumab.
France · Spain · Italy - recruitingPHASE1, PHASE2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
This study looks at a new drug, zongertinib, for different HER2+ cancers that have spread. Researchers want to find the best dose, alone and with other treatments, to see if it can shrink tumours.
United States · Belgium · China - authorisedPhase II and Phase III (Integrated)
A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy on top of first line anti-HER2 targeted treatment of patients with Metastatic Breast Cancer TherO2-01S22 in HER2-positive breast cancer: TherO2-MBC Study
This study is testing a new drug, TherO2-01S22, for people with metastatic breast cancer that is HER2-positive. It aims to see how well it works and if it's safe when added to standard treatments. Researchers want to understand if it can shrink tumours.
France - ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Study to assess the safety and potential use of GEH121224 (18F) Injection to visualise HER2-Receptor expression using PET imaging in patients with Metastatic Breast Cancer
This study looks at a new injection called GEH121224 (18F) to see if it can help doctors find breast cancer that has spread. It uses a special scan called a PET scan to see if cancer cells have a certain marker, called HER2, which can help guide treatment.
Sweden - active not recruitingPHASE1, PHASE2
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This study is testing a new drug, ST101, for people with advanced cancers like breast cancer, melanoma, and glioblastoma. It aims to see if the drug is safe, how much to give, and if it could help shrink tumors. It's for adults whose cancer hasn't responded to other treatments.
United States · United Kingdom - active not recruitingPHASE2
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
This study looks at adding a new drug, ipatasertib, to standard treatment for advanced breast cancer that hasn't responded well to initial therapy. It uses a blood test to identify patients who might benefit most from this additional treatment.
United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II Open Labeled Trial of Disulfiram with Copper in Metastatic Breast Cancer
This study is looking at a new treatment for advanced breast cancer using two existing medicines, disulfiram and copper. Researchers want to see if this combination can shrink the cancer or stop it from growing, and ultimately help people live longer and feel better.
Czechia - authorisedTherapeutic exploratory (Phase II)
Individualized everolimus therapy in metastatic breast cancer
This study looks at how different ways of taking Everolimus medicine affect quality of life for people with metastatic breast cancer. It compares taking the drug once a day versus in smaller doses throughout the day.
Hungary - active not recruitingPHASE2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
This study looks at a new combination of experimental drugs, disitamab vedotin and tucatinib, for advanced breast or stomach cancers that have a specific marker called HER2. It aims to see how safe and effective this treatment is, and what side effects it might cause.
United States · Australia · Canada - recruitingPHASE1, PHASE2
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
This study is testing a new medicine called EP0062 for advanced breast cancer. It aims to find the safest and most effective dose, both alone and with other standard treatments, for women whose cancer has specific features.
United States · Spain · United Kingdom - active not recruitingPHASE1, PHASE2
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
This study is testing a new drug called elacestrant with other breast cancer medicines. It's for people with a specific type of advanced breast cancer that has spread. The main goals are to see if these drug combinations are safe and if they can help shrink the cancer.
United States · Argentina · Australia - ongoing, recruitingPhase II and Phase III (Integrated)
FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: A pilot study for a randomized clinical trial (MONITOR-PILOT)
This study looks at different scans for people with advanced breast cancer. It compares standard CT scans with a special FDG-PET/CT scan to see which better shows how well treatment is working and if it helps people live longer and have a better quality of life.
Denmark - recruitingNA
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
The AURORA study aims to understand advanced breast cancer better. It collects tissue and blood samples from patients across Europe to find out why treatments work or don't. This research could help doctors find the best treatments for each patient in the future.
Belgium · Germany · Iceland - recruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
United States · Australia · France - ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, double-blind, parallel-group, multicentre, phase II study to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo and fulvestrant (FaslodexTM) 500mg in combination with PD-0332991 (Palbociclib) as first line treatment for postmenopausal women with hormone receptor-positive metastatic breast cancer, who have completed at least 5 years of adjuvant endocrine therapy and remained disease free for more than 12 months following its completion or have de novo metastatic disease. "The FLIPPER Study"
This study, called "The FLIPPER Study," is looking at new treatments for women with breast cancer that has spread. It compares a standard drug (Faslodex) with a new combination of Faslodex and another drug (Palbociclib) to see if it works better at stopping the cancer from growing.
Spain · Ireland - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)
This study looks at new drug combinations for advanced breast cancer that has spread. It focuses on a type of breast cancer called 'HER2-low'. Doctors want to see if these combinations are safe, how they work in the body, and if they can help shrink tumours.
Belgium - recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
This study is looking at a new combination of treatments, Inavolisib and Phesgo, for HER2-positive breast cancer that has spread. We want to see if this new combination works better and is safe compared to Phesgo alone after initial treatment.
United States · Argentina · Australia - active not recruitingPHASE1, PHASE2
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
This study is looking at new combinations of medicines for HER2-positive breast cancer that has spread. It aims to see how safe and effective these combinations are in patients whose advanced breast cancer has come back or spread.
United States · Australia · Brazil - active not recruitingPHASE2
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
This study is testing a new combination treatment for advanced breast cancer. It combines a drug called belzutifan with fulvestrant, comparing it to standard hormone therapy. The goal is to see if this new approach is effective and safe for people whose cancer has spread and is hormone-sensitive.
United States · Argentina · Canada - recruitingPHASE1, PHASE2
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
This study is testing two new treatments, BNT323 and BNT327, for advanced breast cancer. It aims to find the safest and most effective dose when used together, and to see if this combination helps patients with different types of breast cancer.
United States · Canada · China - ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II trial of trastuzumab deruxtecan in first-line treatment HER2-positive locally advanced or metastatic breast cancer (MBC) patients considered resistant to trastuzumab + pertuzumab + taxane due to early relapse. “TRANSCENDER Study”
The TRANSCENDER study is a clinical trial looking at a new treatment called trastuzumab deruxtecan (DS-8201a) for advanced breast cancer. It's for patients whose cancer has come back quickly after standard treatments. We want to see how well this new treatment shrinks the cancer.
Spain - recruitingPHASE4
Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
This study looks at whether taking cancer medicines in the morning or evening makes a difference for people with advanced breast or prostate cancer. It also checks if the study plan works well for a bigger future trial.
Canada - recruitingPHASE3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
This study looks at a new drug, palazestrant, combined with standard treatment (ribociclib) for advanced breast cancer that is ER-positive and HER2-negative. It compares this new combination to the standard treatment alone to see if it works better and is safe for people who haven't had other treatments for their advanced cancer.
United States · Australia · Austria - authorisedTherapeutic exploratory (Phase II)
A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm.
This study is for women with advanced hormone-positive, HER2-negative breast cancer that has spread. It aims to find the best second treatment by looking at changes in their blood. Researchers want to see which treatments work best to shrink cancer or stop it from growing for at least six months.
Italy - recruitingPHASE3
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
This study is testing a new drug, sacituzumab govitecan, for people with an advanced type of breast cancer called triple-negative breast cancer. It's for those whose cancer has continued to grow after other treatments. The aim is to see how well it works and understand who it helps most.
France - recruiting
DESTINY Breast Respond HER2-low Europe
This study looks at a medicine called Trastuzumab deruxtecan (T-DXd) for advanced breast cancer that's HER2-low. It aims to understand how patients use it in real life, how well it works, and if they have any side effects, along with other chemotherapy options.
Austria · Belgium · Denmark - recruitingPHASE1
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
This study looks at combining two drugs, palbociclib and avelumab, for a specific type of advanced breast cancer called triple negative. We want to find the safest dose and see how well it works, especially for cancers with a particular marker called AR.
United Kingdom - recruitingPHASE3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
This study compares a new medicine called palazestrant with standard treatments for advanced breast cancer that has grown despite previous hormone therapy. It's for men and women whose cancer is ER-positive and HER2-negative.
United States · Argentina · Australia - active not recruitingPHASE3
Detect V / CHEVENDO (Chemo vs. Endo)
This study compares different treatments for advanced breast cancer that has spread. It aims to see if a combination of targeted therapies and hormone therapy works better than targeted therapies and chemotherapy, while also keeping quality of life high.
Germany - active not recruitingPHASE2
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
This study is testing a new combination of treatments, abemaciclib and tamoxifen, or abemaciclib alone, for women with advanced breast cancer that has spread. It aims to see if these treatments are safe and effective for patients who have already had previous therapies.
United States · Argentina · Austria - recruitingPHASE1
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
This study is testing a new drug called IPH5301 for advanced cancers like breast, stomach, and lung. It's a first-time-in-human study, meaning it's the very first time this drug is being given to people. Researchers want to find a safe dose, either alone or with other treatments.
France - recruiting
Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution
This study aims to understand how breast cancer changes over time, especially when it spreads. Researchers will take several small tissue samples and blood tests from different areas to see how the cancer evolves. This could help develop better treatments in the future.
United Kingdom - active not recruitingPHASE2
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
This study looks at using detailed tumour gene testing to guide treatment for advanced breast cancer. It compares giving targeted drugs based on these tests with standard chemotherapy or immunotherapy for patients whose cancer has responded well to initial treatment.
France - recruiting
CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer
This study helps doctors choose the best treatments for advanced breast cancer. It does this by looking closely at the cancer's unique genetic information. The goal is to find treatments that are a much better match for each patient, based on their specific cancer.
Germany - recruitingPHASE3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
This study compares two drug combinations, RLY-2608 with fulvestrant, and capivasertib with fulvestrant, for advanced breast cancer that has a specific gene change (PIK3CA mutation) and has grown after previous treatment. It's for HR+/HER2- breast cancer.
United States · Argentina · Australia - recruiting
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
This study looks back at how metastatic breast cancer has been treated in France since 2008. Researchers are collecting existing information from patient records to understand how treatments have changed and what has worked best for people.
France - active not recruitingPHASE3
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
This study looks at a new drug, DB-1303/BNT323, for advanced breast cancer that's 'HER2-low' and hormone-positive. It compares the new drug to standard chemotherapy to see if it can stop the cancer from growing for longer.
United States · Argentina · Australia - recruitingNA
FDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer
This study compares two ways to check how well breast cancer treatment is working: standard CT scans versus special FDG-PET/CT scans. It aims to see if FDG-PET/CT can help people with advanced breast cancer live longer and have a better quality of life by finding changes sooner.
Denmark · Germany · Italy